Your browser doesn't support javascript.
loading
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.
Gallamini, Andrea; Barrington, Sally F; Biggi, Alberto; Chauvie, Stephane; Kostakoglu, Lale; Gregianin, Michele; Meignan, Michel; Mikhaeel, George N; Loft, Annika; Zaucha, Jan M; Seymour, John F; Hofman, Michael S; Rigacci, Luigi; Pulsoni, Alessandro; Coleman, Morton; Dann, Eldad J; Trentin, Livio; Casasnovas, Olivier; Rusconi, Chiara; Brice, Pauline; Bolis, Silvia; Viviani, Simonetta; Salvi, Flavia; Luminari, Stefano; Hutchings, Martin.
Afiliación
  • Gallamini A; Research and Medical Innovation Department, Centre Antoine Lacassagne, Nice, France gallamini.a@ospedale.cuneo.it.
  • Barrington SF; Division of Imaging, King's College London, PET Centre, Guy's & St. Thomas' Hospital, London, UK.
  • Biggi A; Nuclear Medicine Department, PET Center, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.
  • Chauvie S; Medical Physics Unit, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.
  • Kostakoglu L; Department of Radiology, Division of Nuclear Medicine, Mount Sinai Medical Center, New York, NY, USA.
  • Gregianin M; Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.
  • Meignan M; Nuclear Medicine Department, Centre Universitaire Hospitalier Henri Mondor, Creteril, Paris, France.
  • Mikhaeel GN; Clinical Oncology Department. Guy's & St. Thomas' Hospital, London, UK.
  • Loft A; PET & Cyclotron Unit, Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Denmark.
  • Zaucha JM; Department of Oncology, Gdynia Oncology Centre & Department of Propedeutic Oncology, University of Gdansk, Poland.
  • Seymour JF; Haematology Department, Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, Parkville Victoria, Australia.
  • Hofman MS; Center for Cancer Imaging Peter Mac Callum Cancer Center, Melbourne, Australia.
  • Rigacci L; Hematology Department, University of Florence, Careggi Hospital, Italy.
  • Pulsoni A; Cellular Biotechnology and Hematology Department, Sapienza University, Rome, Italy.
  • Coleman M; Hematology-Oncology Division, Center for Lymphoma & Myeloma, Weill Cornell Medical Center, New York, NY, USA.
  • Dann EJ; Department of Hematology & Bone Marrow Transplantation; Rambam Medical Center, Haifa, Israel.
  • Trentin L; Hematology Department, University of Padua, Italy.
  • Casasnovas O; Hematology Department, Hopital Le Bocage, Dijon, France.
  • Rusconi C; Hematology Department - Niguarda Ca' Granda Hospital, Milan, Italy.
  • Brice P; Hematology Department Centre Hospitalier Universitaire St. Louis, Paris, France.
  • Bolis S; Hematology Department, S. Gerardo University Hospital, Monza, Italy.
  • Viviani S; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Salvi F; Department of Hematology, SS Antonio e Biagio Hospital, Alessandria, Italy.
  • Luminari S; Onco-Hematology Department, Modena University, Italy.
  • Hutchings M; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.
Haematologica ; 99(6): 1107-13, 2014 Jun.
Article en En | MEDLINE | ID: mdl-24658820
A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P<0.0001). The sensitivity, specificity, and negative and positive predictive values of interim positron emission tomography scans for predicting treatment outcome were 0.73, 0.94, 0.94 and 0.73, respectively. Binary concordance amongst reviewers was good (Cohen's kappa 0.69-0.84). In conclusion, the prognostic role and validity of the Deauville five-point scale for interpretation of interim positron emission tomography scans have been confirmed by the present study.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Tomografía de Emisión de Positrones Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2014 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Tomografía de Emisión de Positrones Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2014 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Italia